在术后辅助治疗阶段,RATIONALE-315研究创新性的采用了替雷利珠单抗400mg Q6W 8周期方案,与其他研究术后Q3W或Q4W给药模式相比,RATIONALE-315研究“6周给药一次”的模式,让辅助治疗阶段仅需用药8次,既不影响患者用药的安全性和有效性...
在术后辅助治疗阶段,RATIONALE-315研究创新性的采用了替雷利珠单抗400mg Q6W 8周期方案,与其他研究术后Q3W或Q4W给药模式相比,RATIONALE-315研究“6周给药一次”的模式,让辅助治疗阶段仅需用药8次,既不影响患者用药的安全性和有效性,同时也有利于提高患者持续治疗的依从性和生活质量,减小临床治疗及长期随访的压力,...
张鹏教授:在获得如此优异疗效的基础上,RATIONALE-315研究还有着极具巧思的方案设计,有望为临床带来创新治疗方案选择。 在新辅助治疗阶段,RATIONALE-315研究前瞻性地采用了3-4周期方案,这样的设计更符合新辅助治疗的初衷,不仅可以最大程度激活抗肿瘤免疫反应,在术前有效缩瘤降期,同时也充分满足了临床实践中针对每位患者...
LBA58 pathological complete response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (ph3) RATIONALE-315 trial. Ann Oncol. 2023;34(suppl 2):S1299. doi: 10.1016/j.annonc....
163P: Transportability of RATIONALE-315 trial outcomes to the European patient population in resectable non-small cell lung cancerdoi:10.1016/S1556-0864(25)00357-0F. PassigliaOncology Department, Università Degli Studi di Torino - Orbassano, Orbassano, ItalyE. Priedane...
全面布局、探索不止,III期注册临床研究包括了针对不可切除局晚及晚期鳞状NSCLC的RATIONALE 307研究;针对不可切除局晚及晚期非鳞状NSCLC的RATIONALE 304研究;针对经治局晚及晚期NSCLC的全球多中心RATIONALE 303研究;针对广泛期SCLC一线治疗的...
LBA58 Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial Author links open overlay panelD. Yue 1, W. Wang 2, H. Liu 3, Q. Chen 4, C....
) over-expressed uterine serous EC(USC). EpCAM expression is found in 87.5% of USC which has been demonstrated to be susceptible to solitomab, a type of EpCAM/CD3 bispecific antibody. The clinical efficacy of solitomab has been noted in multiple cancers such as colon cancer and OC [315...
Retaining teeth in their corrected positions following orthodontic treatment is one of the most challenging aspects of orthodontic practice. Despite much research, the rationale for retention is not entirely clear. Teeth tend to revert to their pre-treatment positions due to periodontal and gingival, ...
(AEs) were observed in 74% of patients, most of which were at low grade and manageable, such as endocrine disorders (i.e. hypothyroidism). This trial expanded the therapeutic value of ICBs from canonical MMR-d colorectal cancers to more MMR-d tumor types and drew researchers’ attention to...